Compare Delta Air Lines, Inc. (DAL) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs Cassava Sciences Inc — how do they compare? Delta Air Lines, Inc. trades at $81.28 (market cap $54.02B), while Cassava Sciences Inc trades at $0.83 (market cap $39.40M). The key difference: Delta Air Lines, Inc. is far larger — about 1371.1× Cassava Sciences Inc's market cap, and Delta Air Lines, Inc. pays a 1.05% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Delta Air Lines, Inc. for 97 Days and Cassava Sciences Inc for 37 Days on average.
| DAL | FLNA | |
|---|---|---|
Market Cap | $54.02B | $39.40M |
Volume | 9,632,845 | 759,018 |
Sector | Industrials | Health |
52-Week High | $93.66 | $4.64 |
52-Week Low | $55.65 | $0.68 |
Typical Hold Time | 97 Days | 37 Days |
Enterprise Value | $69.34B | -$43.28M |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $80.49, down 2.99% on the day, as technical indicators signal bearish momentum with the stock testing support near $80. Fundamentally, the company shows solid profitability with a 5.78% net margin and 20.12% ROE, though Q3 2026 earnings missed expectations. Recent news highlights competitive pressures from United and American's customer poaching efforts and Delta's decision to use Amazon's in-flight internet instead of Starlink.
The investment outlook remains positive with strong analyst support (82% buy ratings) and a $103.36 consensus price target offering 28% upside. Key risks include fuel cost volatility, rising crew expenses, and competitive threats to premium customer retention. Cash flow trends show improvement with net positive flows since 2024.
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
